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ABSTRACT: The modulation of drug metabolism enzyme (DME) expression by therapeutic agents
is a central mechanism of drug−drug interaction and should be assessed as early as possible in
preclinical drug development. Direct measurement of DME levels is typically achieved by Western
blotting, qPCR, or microarray, but these techniques have their limitations; antibody cross-reactivity
among highly homologous subfamilies creates ambiguity, while discordance between mRNA and
protein expression undermines observations. The aim of this study was to design a simple targeted
workﬂow by combining in vivo SILAC and label-free proteomics approaches for quantiﬁcation of
DMEs in mouse liver, facilitating a rapid and comprehensive evaluation of metabolic potential at the
protein level. A total of 197 peptides, representing 51 Phase I and Phase II DMEs, were quantiﬁed by
LC-MS/MS using targeted high resolution single ion monitoring (tHR/SIM) with a deﬁned mass-to-
charge and retention time window for each peptide. In a constitutive androstane receptor (Car)
activated mouse model, comparison of tHR/SIM-in vivo SILAC with Western blotting for analysis of
the expression of cytochromes P450 was favorable, with agreement in fold-change values between
methods. The tHR/SIM-in vivo SILAC approach therefore permits the robust analysis of multiple
DME in a single protein sample, with clear utility for the assessment of the drug−drug interaction potential of candidate
therapeutic compounds.
KEYWORDS: drug metabolism, drug−drug interaction, constitutive androstane receptor, protein quantiﬁcation, targeted in vivo SILAC
■ INTRODUCTION
The United States Food and Drug Administration and
European Medicines Agency advise that, to improve safety in
clinical development and postapproval, the potential for a new
therapeutic agent to interact with established medications
(drug−drug interaction, DDI) should be assessed as early as
possible during preclinical development.1,2 One major mech-
anism of DDI is the ability of chemical agents to regulate the
expression of drug metabolism enzymes and transporters, often
through the modulation of nuclear hormone receptor (NHR)
activity, thereby altering the eﬃcacy of both themselves and
other compounds. It is valuable, therefore, to have a
comprehensive understanding of the levels of expression of
these protein factors and how they are modulated during
therapy.
In the liver, the primary site of drug metabolism, the majority
of phase I (modiﬁcation) reactions are carried out by
cytochrome P450 (CYP), with additional contributions made
by alcohol dehydrogenase (ADH), aldehyde dehydrogenase
(ALDH), aldo-keto reductase (AKR), epoxide hydrolase
(EPHX), and ﬂavin-containing monooxygenase (FMO) super-
families.3 UDP glucuronosyltransferases (UGT) and gluta-
thione S-transferases (GST) enact most phase II (conjugation)
events.3 During laboratory study, if a broad expression proﬁle of
these DMEs is required, DNA microarray or high-density RT-
PCR arrays are typically employed. While providing a
practicable platform for this type of analysis, there is a
signiﬁcant discordance between mRNA and protein expres-
sion.4−6 A recent study by Ohtsuki and colleagues demon-
strated a poor correlation between protein and mRNA levels
for multiple CYP, UGT, and drug transporters, with only a
handful of exceptions.7 In this study, the direct measurement of
protein expression, as opposed to the measurement of mRNA,
correlated far better with enzymatic activity and is therefore a
more appropriate readout for the evaluation of drug−drug
interaction potential.7
Western blotting and other antibody-based approaches are
the mainstay of protein expression analysis for DME, but our
lab and others routinely struggle to interpret data due to the
high degree of sequence homology of superfamily members,
and hence cross-reactivity of antibody preparations. In order to
circumvent this issue, recent developments have been made in
stable isotope dilution mass spectrometry-based proteomics to
simultaneously detect and quantify CYP and other drug
metabolism related proteins.7−13 These studies utilize an
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absolute quantiﬁcation technique (AQUA) where known
quantities of multiple synthetic stable isotope peptides for a
protein/proteins of interest are spiked into proteolytic protein
digests derived from liver samples, prior to LC-MS/MS analysis
in a multiple reaction monitoring (SRM) mode.14 The “heavy”
stable isotope peptides and “light” unlabeled peptides co-elute,
co-ionize, and are only diﬀerentiated by the diﬀerence in mass
through LC-MS/MS analysis. Using peak intensity ratios of the
pairs of light and heavy isotopes, concentrations of analyte
peptides can be calculated based on known concentrations of
the stable isotope peptides. A modiﬁed version of this
procedure using stable isotope-labeled proteins expressed in
and puriﬁed from Escherichia coli as internal standards has also
been developed which, post-translational modiﬁcation and
extraction variability excepted, accounts for eﬃciency of
enzymatic digestion.15,16 But for comprehensive proteomic
analysis, stable isotope labeling by amino acids in cell culture
(SILAC) or in whole organisms (in vivo SILAC, SILAM)
permits the simultaneous quantiﬁcation of thousands of
proteins with a much improved conﬁdence due to the fact
that both light and heavy analytes share near-identical chemical
properties and environment.17−22
Label-free shotgun proteomics is an alternative commonly
used mass spectrometry based proteomics strategy.23 There are
two mainstream label-free based LC-MS/MS approaches based
on either spectral counting or ion intensity. The former
compares the number of MS2 spectra assigned to a protein
between samples, while the latter compares intensities of each
precursor ion between samples. Ion intensity is generally
considered to provide more detailed quantitative information.
This approach aligns precursor ions between all LC-MS/MS
runs using deﬁned retention time and m/z windows. The signal
intensities in each window for each sample are then integrated,
normalized and compared between samples or groups.
Precursor ions showing signiﬁcant diﬀerences or all precursors
with MS2 spectra can then be identiﬁed. The success of this
approach relies on tight control in sample processing and
consistency in retention time in LC separation.
In the current study, we harness the advantages of in vivo
SILAC materials in conjunction with the label-free shotgun
proteomics concept to quantify DMEs in mouse liver, although
the approach could be used for targeted quantiﬁcation of any
detectable protein or protein group of interest. Peptides from
DMEs were identiﬁed in a metabolically labeled spike-in
standard lysate and a complementary list of unlabeled peptides
was constructed. This list of peptide pairs was stress-tested with
a range of heavy to light input sample ratios and only the most
reliable were retained. The ﬁnal peptide list allowed us to
quantify changes in expression of 51 DMEs and was used to
generate a constitutive androstane receptor (Car) activation
signature.
■ MATERIALS AND METHODS
Reagents
1,4-Bis-[2-(3,5-dichloropyridyloxy)]benzene, 3,3′,5,5′-tetra-
chloro-1,4-bis(pyridyloxy)benzene (TCPOBOP), corn oil, DL-
dithiothreitol, and iodoacetamide were purchased from Sigma
(Dorset, UK). Trypsin Gold was purchased from Promega
(Madison, WI). Lys(6)-SILAC-mouse tissue was purchased
from Silantes (Munich, Germany).
Animal Husbandry and Dosing
All mice were maintained under standard animal house
conditions, with free access to food and water, and a 12 h
light/12 h dark cycle. All animal work was carried out on male
8-week-old C57BL/6J mice in accordance with the Animal
Scientiﬁc Procedures Act (1986) and after local ethical review.
Mice were administered either TCPOBOP (a single intra-
peritoneal injection at 3 mg/kg) in corn oil vehicle at 10 μL/g
body weight, or the same volume of corn oil vehicle alone.
Animals were sacriﬁced 7 days after dosing, and liver tissue
excised and snap-frozen in liquid nitrogen for storage at −80
°C.
Sample Preparation
For LC-MS/MS, frozen liver tissue was thawed by addition of 9
volumes of SDT lysis buﬀer (4% SDS, 0.1 M DTT, 100 mM
Tris-HCl pH7.6) then homogenized by rotor-stator (2 × 5 s at
20k revolutions). Homogenate was heated to 95 °C for 5 min,
sonicated (2 × 5 s), and then centrifuged at 16 000 g for 10
min. Supernatant (protein sample for analysis) was removed,
aliquoted and stored at −80 °C until use. Protein samples (total
of 30 μg/well) were electrophoresed through a 12% bis-tris gel
in MOPS running buﬀer supplemented with antioxidant (all
Life Technologies, Paisley, UK) alongside a Spectra multicolour
broad range protein ladder (Thermo Fisher Scientiﬁc,
Waltham, MA). Gels were stained with Coomassie blue,
destained, and then rehydrated with Milli-Q water. Gel regions
containing proteins of interest, as described in the Results
section, were removed with a clean scalpel, sliced ﬁnely (ca. 1 ×
1 mm cubes), and added to 1.5 mL PCR-clean eppendorf tubes
(Eppendorf, Hamburg, Germany). In-gel trypsin digest and
peptide extraction was carried out according to the method of
Schevchenko and colleagues.24 Peptide sample concentration
was determined by Nanodrop (Thermo Fisher Scientiﬁc) and
adjusted to 0.2 mg/mL in water containing 0.1% (v/v)
triﬂuoroacetic acid. For Western blotting, microsomal lysates
were prepared and analyzed as described previously.25,26 Brieﬂy,
tissue was homogenized in 3 volumes of KCl buﬀer (1.15% w/v
potassium chloride, 10 mM potassium phosphate, pH7.4) by
rotor-stator (2 × 5 s at 20k revolutions) followed by
centrifugation at 11 000g for 15 min. Supernatant was
ultracentrifuged at 100 000g for 1 h and the resulting pellet
resuspended in KCl buﬀer containing 0.25 M sucrose. Protein
concentration was adjusted to 1 mg/mL in LDS sample buﬀer
(Life Technologies) before electrophoresis through 10%
acrylamide gels for 1 h at 200 V, followed by transfer onto
nitrocellulose membranes (1 h at 100 V). Ponseau S and/or
coomassie staining were used to ensure even loading. Our in-
house panel of rabbit polyclonal antibodies for Cyp detection
has been summarized previously.27 Fold changes were
calculated from chemiluminescent signal intensity on a Fujiﬁlm
LAS-3000 imager (Fujiﬁlm, Tokyo, Japan).
Liquid Chromatography and Mass Spectrometry
A nanoﬂow liquid chromatograph (Agilent 1200, Agilent, Santa
Clara, CA) with a LTQ-Orbitrap XL (Thermo Fisher
Scientiﬁc) was used to analyze the protein digests. Approx-
imately 0.4 μg total peptide was loaded onto a trap column at a
ﬂow rate of 10 μL/min for 3 min and the ﬂow was then
reversed to an Agilent Zorbex nano C18 column (0.0075 mm
ID; 15 cm; 3 μm particle size). The peptides were resolved with
a 3 h binary gradient at a ﬂow rate of 300 nL/min as follows:
0% buﬀer B for 5 min followed by 2−30% buﬀer B for 140 min,
30−90% buﬀer B for 15 min, 90−0% buﬀer B for 10 min, and
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0% buﬀer B for 10 min. Buﬀer A contained 2% acetonitrile and
0.1% formic acid in water, and buﬀer B contained 0.1% formic
acid in acetonitrile. The column was periodically cleaned with a
2 μL injection of buﬀer containing 50% acetonitrile and 0.1%
formic acid in water. A Proxeon nanospray source with a
stainless steel emitter (Thermo Fisher Scientiﬁc) was used to
interface the Agilent nanoLC and LTQ-Orbitrap. Spray voltage
was set at 1.8 kV. The Orbitrap was tuned using Glu-
Fibrinogen B peptide. For the protein/peptide identiﬁcation, a
method that consisted of full scans between 330 and 1500 amu
(in Orbitrap) and data dependent MS/MS with top six
precursor ions (2+ to 4+ charged) in LTQ was employed.
Orbitrap was operated in a proﬁle mode at the resolution of 30
000 or 60 000 with a lock mass set at 445.1200 (poly-
cyclodimethylsiloxane28), and LTQ was operated in a centroid
mode with isolation width = 1 (m/z), normalized collision
energy = 0.25, and activation time = 30 ms. The max ﬁll times
for Orbitrap and LTQ were set at 500 and 50 ms, respectively.
A dynamic exclusion of 30 s was used to maximize the
acquisition of MS2 on peptides with lower intensity. For tHR/
SIM analysis, a method that consisted of full scans between 330
and 1500 a.m.u (in Orbitrap) and data dependent MS/MS
scans with or without deﬁned precursors was employed. A
dynamic exclusion of 30 s and a threshold of 500 counts to
trigger MS2 were also applied for MS/MS scans. Nontargeted
data dependent MS/MS was performed when there was no
targeted precursor found in the MS scan. Further details can be
found in the method and tune ﬁles (Supporting Information
Files S-1 and S-2).
Data Analysis
Protein and peptide database search was carried out using
PEAKS version 6 (Bioinformatics Solutions, Waterloo, Canada)
with an IPI-mouse database (version 3.87, European Bio-
informatics Institute, Hinxton, UK). The precursor mass
tolerance was set at 7 ppm, and fragment ion mass tolerance
set at 0.5 amu. The only permitted post-translational
modiﬁcations were N-terminal acetylation and cysteine
carbamidomethylation, while a maximum of two miscleavages
were allowed. Quantiﬁcation of the predeﬁned targeted
peptides was carried out using SIEVE version 2.0 (Thermo
Fisher Scientiﬁc) using two seed ﬁles, one for each DME region
of interest, containing retention time and m/z information. The
precursor mass tolerance was set to 5 ppm, and the minimal
intensity for alignment was set at 100 000, with intensities
derived from the ﬁrst monoisotopic peak. Data from SIEVE
were exported to Excel 2010 (Microsoft, Redmond, WA) for
calculation of light to heavy peptide ratios. For protein
quantiﬁcation, light to heavy protein ratios were calculated
within samples by summing average intensity values for all light
peptides for each protein, then dividing by the corresponding
heavy value. Light to heavy protein ratios for technical
replicates were averaged then biological replicates normalized
to the average of control, before calculation of fold changes. For
calculation of statistical signiﬁcance, normalized values were
Figure 1. tHR/SIM-in vivo SILAC workﬂow. (A) Metabolically labeled mouse liver tissue lysates were combined 1:1 with experimental sample
lysates for SDS-PAGE. Excised bands were processed by in-gel trypsin digestion for LS−MS/MS analysis. Heavy/light ratios from the ﬁrst
monoisotopic peaks were calculated for each peptide of interest in individual samples, with fold changes across samples calculated using the ratio/
ratio value. (B) The gel bands excised, region 1 (66−40 kDa) and region 2 (40−22 kDa), are predicted to contain the DMEs of interest.
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log2-transformed and then analyzed by unpaired Student’s t
test (FDR = 0.5%) using Prism 6 (GraphPad, La Jolla, CA); *p
< 0.05, **p < 0.01, ***p < 0.001.
■ RESULTS
Concept of tHR/SI-in Vivo SILAC Workﬂow
A workﬂow schematic of the tHR/SIM in vivo SILAC approach
is shown in Figure 1A. Liver lysates were combined 1:1 with a
liver lysate from metabolically labeled in vivo SILAC animals,
which served as an internal standard for each experimental
sample. Gel electrophoresis was selected for sample prepara-
tion, as it allowed for fractionation and enrichment of DMEs at
the protein level. This selection was based on a pilot
comparison of the SDS-PAGE in-gel digestion method to
FASP. In the former, DMEs were resolved by SDS-PAGE into
two deﬁned molecular weight regions which were excised for
analysis; DME region 1 (66−40 kDa) was expected to contain
Adh, Aldh, Cyp, Fmo, Ugt, and Ephx enzymes, while DME
region 2 (40−22 kDa) was expected to contain Akr, Gst, N-
acetyltransferase (Nat), and sulfotransferase (Sult) enzymes,
based on calculated MW values (Figure 1B). Protein in excised
bands was reduced, alkylated, and digested with trypsin
according to published protocols.24 Peptides were extracted
and analyzed by LC−MS/MS, wherein MS2 data were
obtained. A total of 64 DMEs were identiﬁed by PEAKS
analysis after the two-sample in-gel procedure, compared to 49
following the single-sample FASP procedure (Supporting
Information Tables S-1−S-3).
Characterization of in Vivo SILAC Liver
Similar to the principles of stable isotope dilution LC−MS
methods, the accuracy of measurements in tHR/SIM are highly
dependent on the reliable detection of heavy stable isotope
signals. It was therefore important to characterize the liver
proteome of the spike-in reference lysate to determine which
DMEs could be monitored. As detailed above, SDS-PAGE and
in-gel digestion of an in vivo SILAC liver sample permitted
identiﬁcation of a total of 64 DMEs (2 Adh, 7 Akr, 11 Aldh, 23
Cyp, 1 Ephx, 2 Fmo, 9 Gst, 0 Nat, 2 Sult, and 7 Ugt) by unique
peptides (FDR = 0.1%). In addition, due to the high degree of
identity shared by certain enzymes, some were unidentiﬁable by
unique peptides but were nonetheless retained as protein
groups, for example, Cyp2a4/2a5. Peptides without lysine were
removed from the list, as were those with −10Log P values
<17.3 (FDR = 0.1%). This “heavy-only” peptide list was
converted to a list of SILAC peptide pairs by addition of the
predicted counterpart light members. The utility of these
peptide pairs for quantiﬁcation was then stress-tested as follows.
An unlabeled liver lysate was mixed with the in vivo SILAC liver
lysate at ratios of 1:1, 1:4, and 1:16 in duplicate for processing
and analysis by LC−MS/MS. The MS data were analyzed in
SIEVE using the SILAC peptide pair list as a seed ﬁle
(retention time window of ±5 min). Light to heavy peptide
Figure 2. Analytical performance of Cyp1a2 tryptic peptides. (A) Using a ±5 min retention time window (gray boxes), nontarget signals could be
eﬀectively gated from NSIQDITSALFK and FLTNNNSAIDK peptide pair quantiﬁcation. (B) Dilution linearity of the NSIQDITSALFK peptide
pair achieved R2 of 0.998, while MS2 spectra were acquired for both (C) light and (D) heavy forms, conﬁrming their identity.
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ratios were calculated using average intensity values. The
average ratio value from technical replicates was then log4
transformed to evenly distribute the three data points, allowing
calculation of an equally weighted R2 value. Only those peptides
showing strong linearity (R2 > 0.9) were retained. The data
output from SIEVE, along with calculations of R2 values, can be
found in Supporting Information Tables S-4 and S-5.
Approximately 57% of identiﬁed peptides survived this ﬁltration
step (Supporting Information Figure S-1). Seed ﬁles containing
m/z and retention time windows for each peptide can be found
in Supporting Information Tables S-6 (DME region 1) and S-7
(DME region 2).
An example of tHR/SIM in vivo SILAC is shown in Figure 2.
Three Cyp1a2 peptides were used to deﬁne Cyp1a2 levels, one
of which eluted at 37.9 min and another at 94.7 min (Figure
2A). Although some interfering signals were observed, these
could be separated from the signals of interest by retention time
gating and the matching of internal standard signals. For one of
these peptides, NSIQDITSALFK, an R2 value for linearity of
0.998 was observed (Figure 2B) and the identities of both the
light and heavy forms could be conﬁrmed by their MS2 (Figure
2C and D).
Validation of tHR/SIM by Comparison to Western Blotting
To compare the output of tHR/SIM in vivo SILAC to Western
blotting, we assessed the Cyp induction proﬁle in mice treated
with a potent and speciﬁc inducer of the constitutive
androstane receptor, TCPOBOP. Animals (n = 3) were
administered the compound in corn oil, and, after 7 days,
livers were harvested for analysis. Western blotting for Cyp
indicated strong induction of multiple family members,
compared to vehicle control (Figure 3A). Depending on the
origin of antisera, as well as results of previous studies (not
shown), the exact identity of individual enzymes may or may
not be known. With our in-house panel of antibodies, up-
regulation could be demonstrated for Cyp1a1 (46.5-fold),
Cyp1a2 (5.1-fold), Cyp2b10 (362.9-fold), and 3a11 (5.7-fold),
while down-regulation could be demonstrated for Cyp2e1 (0.8-
fold), as these superfamily members are predictably and
reproducibly identiﬁed. For other antisera, such as Cyp2c and
Cyp2d, the precise identities of the proteins detected are
unknown, so, although inductions are observed, these are not
Figure 3. tHR/SIM-in vivo SILAC compared to Western blotting. Cyp isoform in TCPOBOP-treated mice (n = 3), as compared to corn oil vehicle-
treated control animals (n = 3), were measured by (A) Western blot and (B) tHR/SIM-in vivo SILAC (black bars, corn oil; gray bars, TCPOBOP).
Following Western blot of pooled samples, chemilluminescent signal was used to quantify fold changes in particular bands (red boxes), with values
presented alongside. If known, the isoform detected is given in brackets. Note that, in the control, some protein levels were below the limit of
detection by Western blotting (e.g., Cyp2b10) and therefore the fold changes calculated may not be accurate. For tHR/SIM-in vivo SILAC, the
number of unique peptides used to calculate fold change is given (gray text), and as samples for individual animals were analyzed separately, error
bars are a reﬂection of biological variability, as well as technical error.
Figure 4. tHR/SIM-in vivo SILAC analysis of modulation of additional DMEs by TCPOBOP. (A) Other phase I and (B) phase II enzymes were
quantiﬁed. Black bars, corn oil; gray bars: TCPOBOP.
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attributable to any family member in particular. For t-HR/SIM-
in vivo SILAC, data for individual animals were acquired and
processed separately, and then average fold changes ± SD
calculated at the last stage, to account for biological variability.
Cyp1a2 (3.5-fold), Cyp2a4/5 (16.2-fold), Cyp2c29 (15.7-fold),
Cyp2c37 (9.5-fold), Cyp2d22 (2.5-fold), Cyp3a13 (5.3-fold),
and Cyp8b1 (3.1-fold) were signiﬁcantly up-regulated (Figure
3B). Although not statistically signiﬁcant (p = 0.08), Cyp2e1
levels were decreased (0.87-fold). Due to the low abundance of
Cyp1a1, Cyp2b10, and Cyp3a11 in the spike-in standard, these
enzymes could not be quantiﬁed by LC−MS/MS. Never-
theless, there was close agreement between methods of changes
in Cyp1a2 and Cyp2e1 expression. Moreover, Western blotting
suggested induction of unconﬁrmed Cyp2c, Cyp2d, and Cyp3a
family members, while LC−MS/MS demonstrated induction of
Cyp2c29, Cyp2c37, Cyp2d22, and Cyp3a13.
To provide additional conﬁdence that the assay was reliable,
we extracted data for four proteins/protein families which are
not expected to change signiﬁcantly following TCPOBOP
dosing: pro/albumin, calreticulin, α-tubulin, and β-tubulin.
None of these changed signiﬁcantly (Supporting Information
Figure S2).
Additional DME Changes in Response to TCPOBOP
Of the other quantiﬁable phase I enzymes, Aldh1a1 (3.1-fold)
and Fmo5 (3.1-fold) were signiﬁcantly up-regulated, while
Aldh2 (0.4-fold) and Aldh6a1 (0.5-fold) were signiﬁcantly
down-regulated (Figure 4A). For phase II, Gsta3 (1.6-fold),
Gstm1 (7.5-fold), Gstt3 (7.0-fold), Sult3a1 (4.7-fold), Ugt1a1/
2 (2.9-fold), Ugt2b34 (3.8-fold) and Ugt2b36 (1.8-fold) were
signiﬁcantly up-regulated (Figure 4B). Ugt2a3 (0.8-fold) was
the only enzyme for which signiﬁcant down-regulation
occurred.
■ DISCUSSION
Through the combination of in vivo SILAC and label-free
approaches we have created a streamlined and simple targeted
proteomics workﬂow permitting the quantitative analysis of 51
DMEs in the mouse. This technique has utility in the
investigation of pharmacodynamics, particularly when the
potential for, or occurrence of, drug−drug interaction is in
question. Upstream, the use of metabolically labeled isotopic
tissue as an internal standard reduces experimental variation
derived from sample processing and ionization. This is
especially important when error-prone methods such as in-gel
digestion are used, and when the diﬀerence between
experimental groups is relatively small. Downstream, the
strategy resembles that of stable isotope dilution LC-MS for
quantiﬁcation of small molecules. The narrow retention time
and m/z windows reduce the inﬂuence of potential
contaminant signals during data processing, while data analysis
is simpliﬁed in comparison to more conventional SILAC
procedures as only a predetermined list of proteins/peptides of
interest is measured, permitting immediate and intuitive
interpretation.
One limitation of the tHR/SIM in vivo SILAC approach is
that changes in expression cannot be monitored in the DME
for which heavy isotope labeled MS2 are not acquired. A
potential solution to this problem would be to rerun a database
search on the experimental MS ﬁles and, where MS2 for light
peptides from nontargeted DME can be detected, manually
interrogate the primary raw ﬁle, referencing the light signal to
other heavy peptides eluted within the same time frame, or to
total ion current as typically performed with label-free
proteomics.29 Caution must be reserved that such quantiﬁca-
tion may be subject to sources of peptide bias, such as
diﬀerential recovery during sample processing and diﬀerential
eﬃciency during ionization. Although in the current study we
believe high resolution SIM mode is suﬃcient to monitor the
levels of 51 DME proteins, mainly due to their higher relative
abundance, the method can be easily adapted to an MRM
mode where the precursor and fragment ion transitions are
monitored.
We have applied the tHR/SIM-in vivo SILAC workﬂow to
the analysis of DME changes in response to the Car activator,
TCPOBOP. With an EC50 of approximately 100 nM, maximally
eﬀective dose of 3 mg/kg, and response duration of greater
than 20 weeks in the mouse, this compound is the most potent
car-speciﬁc inducer known.29−31 It acts as a mitogen,
nongenotoxic tumor-promoter and complete carcinogen.32−34
In the liver, in studies variously employing TCPOBOP and/or
Car knockout mice as tools to characterize the Car-dependent
gene battery, up-regulation of transcription of mRNA has been
demonstrated for Cyp1a1, 1a2, 2a4, 2a5, 2b9, 2b10, 2b13, 2c29,
2c37, 2c55, 2c65, 2f2, and 3a11, with decreases seen for 4a10
and 4a31.35−39 At the protein level, widespread Cyp induction
has been demonstrated by Western blot40 and in a postdigest
18O labeling study, where Cyp1a2, 2a4/5, 2b10, 2b20, 2c29,
2c37, 2c38, 3a11, and 39a1 were shown to be up-regulated,
with Cyp2c40, 2e1, 3a41, and 27a1 down-regulated.41 In the
current study, we detected signiﬁcant up-regulation of Cyp1a2,
2a4/2a5, 2c29, 2c37, 2d22, 3a13, and 8b1 and nonsigniﬁcant
down-regulation of Cyp2e1, broadly in agreement with the
literature, although we did not see the previously reported
changes in Cyp2f2. This could be due to post-transcriptional or
post-translational regulation, or variation in genetic back-
ground. Our data conﬂict with the report of Cyp27a1 down-
regulation,41 as we detected a nonsigniﬁcant increase. We did
not observe any signiﬁcant changes in Adh or Akr but, to our
knowledge, the only previously reported Car/TCPOBOP
target within these superfamilies is Akr1b7,42 which we did
not detect and were therefore unable to quantify. The only
other reported Car/TCPOBOP-regulated members of the
phase I metabolism superfamilies under study are Aldh1a1,
Aldh1a7, and Fmo5, which are up-regulated at the mRNA
level.36,43−45 Our data agree with those for Aldh1a1 and Fmo5,
although we could not detect Aldh1a7 protein. In previous
reports, Aldh1b1, 2, 6a1, and 7a1 have shown a Car/
TCPOBOP-dependent down-regulation.43,44 Our data agree
completely with these observations, although only the more
pronounced decreases in Aldh2 and 6a1 achieve signiﬁcance.
For phase II, at the mRNA level, Car/TCPOBOP can
upregulate Gsta1, a2, a4, m1, m2, m3, m4, t1 and t3, Sult1a1,
1e1, 2a1, 2a2, 3a1 and 5a1, Ugt1a1, 1a9, 2b34, 2b35 and 2b36,
and down-regulate Ugt2a3 and 3a1/2.36,44,46,47 In agreement
with the literature, we observed signiﬁcant induction of Gsta3,
m1, t3 and Sult3a1, and nonsigniﬁcant induction of Gstm2 and
t1, and Sult1a1. For Ugt, we detected induction of Ugt1a1/2,
2b34, and 2b36, with repression of 2a3, all in agreement with
previous (mRNA) reports.36,44,47 Our ﬁndings agree with the
only report we are aware of regarding phase II protein
induction by Car/TCPOBOP, that of Ugt1a1.36 Therefore, as
the vast majority of Car targets have been established as such
from mRNA studies, it is noteworthy that, for many of these
targets, we have provided the ﬁrst evidence for their modulation
at the protein level. Moreover, despite the inﬂuence of post-
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transcriptional and post-translational regulation, we have
demonstrated that the Car activation signature is essentially
conserved from mRNA to protein.
While we found that the tHR/SIM approach is satisfactory
for the analysis of 51 DME proteins using a LTQ-Orbitrap,
other recently developed MS2 based targeted quantitative
proteomics approaches such as SWATH,48 MSE,49 and parallel
reaction monitoring (PRM)50 may provide an alternative if a
quadrupole-Orbitrap or quadrupole-time-of-ﬂight mass spec-
trometer is available. In particular, the PRM approach has
recently been shown to provide better sensitivity and speciﬁcity
than SIM.50 PRM quantiﬁes high resolution fragment ions
signals derived from “light” and “heavy” precursor ion pairs that
are preisolated by a quadrupole, accumulated and fragmented
in a C-trap. It is therefore anticipated that the number of DME
proteins measured could be potentially improved using the
PRM approach.
In conclusion, the application of tHR/SIM-in vivo SILAC for
quantiﬁcation of 51 DME presented here constitutes a
comprehensive means of proﬁling altered capacity for drug
metabolism in the mouse. An appreciation of this capacity is
valuable when carrying out pharmacokinetic studies in this
model organism, when up- or down-regulation of DME
expression due to drug treatment or genetic manipulation has
a bearing on results. Moreover, this approach could provide an
additional measure of the DDI potential of a candidate
therapeutic compound during preclinical development. As
modulation of DMEs typically requires upstream activation of
one or more NHR by direct binding to chemical agents, species
diﬀerences in drug/receptor aﬃnity mean that caution must be
reserved in drawing conclusions from studies in model
organisms. Conceivably, tHR/SIM-in vivo SILAC could be
used to measure DDI potential in NHR-humanized mice, such
as the Car/Pxr double humanized line,51 constituting a more-
accurately modeled in vivo approach and thereby reducing the
gap between preclinical and clinical evaluation of DDI.
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